ELAINE 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- NCT05696626 ↗
- Recruiting
- LeonaBio
- Standard
We haven't built an HCP commentary report on ELAINE 3 (lasofoxifene plus abemaciclib in ESR1-mutated ER+/HER2- locally advanced or metastatic breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ELAINE 3 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 6 | |
| Podcasts | 5 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Lasofoxifene in combination with abemaciclib; Fulvestrant in combination with abemaciclib
- Arms
- Treatment · Experimental
- Reference Therapy · Active comparator
- Enrollment
- 600 (estimated)
- Primary outcomes
- Progression free survival (PFS)
- Sponsor
- LeonaBio
- Start
- Oct 31, 2023
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05696626 · updated Oct 29, 2026
Publications
linked from the registry- Goetz MP, Wander SA, Bachelot T, de Nonneville A, Gal-Yam EN, Sammons SL, Shen S, Twelves C, Boruta G, Portman DJ, Damodaran S. ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer. Future Oncol. 2025 May;21(11):1317-1324. doi: 10.1080/14796694.2025.2481825. Epub 2025 Apr 13. PubMed 40222048